Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer

K. S. Anderson, J. Wong, G. D'Souza, A. B. Riemer, J. Lorch, R. Haddad, S. I. Pai, J. Longtine, M. McClean, J. Labaer, K. T. Kelsey, M. Posner

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Background:Human papillomavirus (HPV) type 16 is associated with oropharyngeal carcinomas (OPC). Antibodies (Abs) to HPV16 E6 and E7 oncoproteins have been detected in patient sera; however, Abs to other early HPV-derived proteins have not been well explored.Methods:Antibodies to the HPV16 proteome were quantified using a novel multiplexed bead assay, using C-terminal GST-fusion proteins captured onto Luminex beads. Sera were obtained from untreated patients with OPC (N40), partners of patients with HPV16 OPC (N11), and healthy controls (N50).Results:Oropharyngeal carcinomas patients with known virus-like capsid particle Abs had elevated serum Abs to HPV16 E1, E2, E4, E6, and E7, and L1 antibody levels, but not E5. The ratios of specific median fluorescence intensity to p21-GST compared with controls were E1: 50.7 vs 2.1; E4: 14.6 vs 1.3; E6: 11.3 vs 2.4; E7: 43.1 vs 2.6; and L1: 10.3 vs 2.6 (each P0.01). In a validation cohort, HPV16 E1, E2, and E7 antibody levels were significantly elevated compared with healthy control samples (P0.02) and partners of OPC patients (P0.01).Conclusion:Patients with HPV16 OPC have detectable Abs to E1, E2, and E7 proteins, which are potential biomarkers for HPV-associated OPC.

Original languageEnglish (US)
Pages (from-to)1896-1905
Number of pages10
JournalBritish journal of cancer
Issue number12
StatePublished - Jun 7 2011


  • HPV
  • Luminex
  • autoantibodies
  • biomarker
  • head and neck cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer'. Together they form a unique fingerprint.

Cite this